Pulmonary vascular disease & thromboembolism
Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis
Authors' conclusion
Twelve-month edoxaban treatment in cancer-associated IDDVT was superior to 3-month edoxaban treatment in terms of thrombotic events without increased bleeding risk among patients with low body weight but with increased bleeding risk among patients with non-low body weight.
Study context
- Population
- Patients with cancer-associated isolated distal deep vein thrombosis (IDDVT), divided by body weight with a 60 kg cutoff426 had low body weight, 99% receiving a reduced dose of edoxaban · low body weight 426
- Participants
- 601 patients
- Comparison
- 12-month and 3-month edoxaban treatments in patients with low body weight and cancer-associated IDDVT
- Primary endpoint
- symptomatic recurrent venous thromboembolism or venous thromboembolism-related death
- Follow-up
- 12 months
Primary result
As reported in the abstract
12-month edoxaban group vs 3-month groupOdds ratio (95% CI)P value
Low body weight subgroup: 1.0% vs 6.2%
0.15(0.02–0.55)
P = 0.003Non-low body weight subgroup: 1.0% vs 10.0%
0.10(0.01–0.54)
P = 0.005Safety
1-year major bleeding rate
- Low body weight subgroup, 12-month vs 3-month (not different)
- 7.0% vs 8.4%, P = 0.57
- Non-low body weight subgroup, 12-month vs 3-month (significantly higher in the 12-month edoxaban group)
- 14.7% vs 3.8%, P = 0.01
Original publication
Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis. JACC Adv. Published 4 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it